| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2005 | US20050043398 such as 2-ethoxycarbonyl-7-hydroxychromone, for the care, preservation or improvement of the general state of the skin or hair |
| 02/24/2005 | US20050043397 Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/24/2005 | US20050043395 Angiogenesis inhibitors; reduced vascular system permeability; anticancer agents; antitumor agents |
| 02/24/2005 | US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate |
| 02/24/2005 | US20050043393 Antilipemic agents |
| 02/24/2005 | US20050043391 Cicletanime and calcium antagonist and, or ace inhibitors |
| 02/24/2005 | US20050043390 Viricides against herpes virus |
| 02/24/2005 | US20050043389 Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments |
| 02/24/2005 | US20050043388 Therapy, prevention of metabolism disorders; insulin resistance; antidiabetic agents; hypoglycemic agents; anticholesterol agents; obesity; polycystic ovarian syndrome |
| 02/24/2005 | US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants |
| 02/24/2005 | US20050043385 Hydroxyalkylindole derivatives as anticancer agent |
| 02/24/2005 | US20050043383 Combined agents for treatment of glaucoma |
| 02/24/2005 | US20050043377 Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition |
| 02/24/2005 | US20050043376 Epothilone A and B; desoxyepothilone A and B; anticancer agenst |
| 02/24/2005 | US20050043375 Solid preparation containing single crystal form |
| 02/24/2005 | US20050043374 Administering to animal drug , or hydrolysable ester thereof |
| 02/24/2005 | US20050043373 Tyrosine phosphatase inhibitor; antidiabetic agents; insulin resistance; obesity |
| 02/24/2005 | US20050043369 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections |
| 02/24/2005 | US20050043368 Osteoporosis therapy; bone disorders |
| 02/24/2005 | US20050043367 Polyamine compounds are used to mobilize and harvest CD34+ cells via apheresis with and without combinations with other mobilizing factors; bind to chemokine receptors; regeneration of heart tissue |
| 02/24/2005 | US20050043366 Antiinflamamtory agents; immunology disorders; autoimmune diseases; antiallergens; aids viricides; antiarthritic agents; muscular disorders; Parkinson's disease; Alzheimer's disease; kidney damage |
| 02/24/2005 | US20050043362 Use of compounds |
| 02/24/2005 | US20050043360 Method for obtaining pioglitazone as an antidiabetic agent |
| 02/24/2005 | US20050043359 Kit for treatment of upper gastrointestinal tract conditions |
| 02/24/2005 | US20050043356 Polymorphic form of rimonabant method for preparing it and pharmaceutical compositions containing it |
| 02/24/2005 | US20050043355 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| 02/24/2005 | US20050043353 Reacting an anhydride with alcohol in presence of catalyst; kinetic resolution |
| 02/24/2005 | US20050043352 human YAK family of serine/threonine protein kinases (hyak); use treating diseases of the hematopoietic systems, including anemias, polycythemia, myelodysplastic syndrome, myelosuppression, cytopenia, male contraceptives; 2-(3-Chloro-phenylamino)-7-methoxy-quinoline-3-carboxylic acid for example |
| 02/24/2005 | US20050043351 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| 02/24/2005 | US20050043350 Administering heterocyclic ether such as 5-chloro-7-hydroxy-3-(4-hydroxyphenylz)-4-oxo-1-benzopyran for prophylaxis of Alzheimer's disease, osteoporosis, cardiovascular disorders, psychological disorders, antiarthritic agents,anxiolytic agents |
| 02/24/2005 | US20050043349 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 02/24/2005 | US20050043348 Phenyl-substituted imidazopyridines |
| 02/24/2005 | US20050043347 N-94-94-amino-7-(3-(dimethylamino)-1-propynyl)thieno93,2-c)pyridin-3-yl)phenyl-N'-(3-methylphenyl)urea; controlling cell differentiation, cell proliferation or metabolism; anticancer agents; antidiabetic agents; antiinflammatory agents |
| 02/24/2005 | US20050043346 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/24/2005 | US20050043345 Opioid receptor antagonist and cannabinoid receptor antagonist for treatment of alcohol, cocaine, and/or tobacco dependence |
| 02/24/2005 | US20050043344 Such as 3-(3,5-ditert-butylphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid; for treatment of tumor metastasis, angiogenesis, osteoporosis, arthritis, retinopathy, smooth muscle cell migration, restenosis, and atheroscelorosis |
| 02/24/2005 | US20050043343 Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
| 02/24/2005 | US20050043342 Methods for treating urinary incontinence and other disorders using trospium |
| 02/24/2005 | US20050043341 For stimulation of reverse cholesterol transport, lowering low density lipoproteins in blood; for treatment of hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, arteriosclerosis adiposity and obesity stroke or Alzheimer's disease |
| 02/24/2005 | US20050043340 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
| 02/24/2005 | US20050043339 Dihydropyrimidone inhibitors of calcium channel function |
| 02/24/2005 | US20050043337 Selective beta3 adrenergic agonists |
| 02/24/2005 | US20050043336 Quinazoline derivatives as antitumor agents |
| 02/24/2005 | US20050043335 Heterocyclic derivatives of glycinamide and their medical use |
| 02/24/2005 | US20050043333 Quinazolinone derivative |
| 02/24/2005 | US20050043332 Such as 4 (cis-3-hydroxycyclopentyl)amino-5,6-dimethyl-2-phenyl-7H-pyrrolo[2,3d] pyrimidine for treatment of adenosine receptor stimulated diseases, cardiovascular disorders, and nervous system disorders |
| 02/24/2005 | US20050043330 Antiinflammation agents |
| 02/24/2005 | US20050043329 Crystalline forms of valacyclovir hydrochloride |
| 02/24/2005 | US20050043328 Such as 6-(2-hydroxy-3-chloroxybenzylamino)purine, 6-(2-hydroxy-4-chlorobenzylamino)purine; agriculture; cloning; immunostimulation |
| 02/24/2005 | US20050043327 Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 02/24/2005 | US20050043326 Compounds |
| 02/24/2005 | US20050043324 Polymorphic forms of ziprasidone HCI and processes for their preparation |
| 02/24/2005 | US20050043323 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/24/2005 | US20050043322 For therapy of hypertension |
| 02/24/2005 | US20050043321 Administering antifungal (terbinafine) and antibiotic, reducing amount of necessary emollients; for treatment of asthma, eczema, sinusitis, bronchitis, and allergic rhinitis |
| 02/24/2005 | US20050043319 Molecular target of neurotoxicity |
| 02/24/2005 | US20050043318 Such as (2R,5S)-1-((4-chloro-2-(aminocarbonyl)phenoxy)methyl)carbonyl-2,5-dimethyl4-(4-fluorobenzyl)piperazine |
| 02/24/2005 | US20050043317 Biaryl heterocyclic compounds and methods of making and using the same |
| 02/24/2005 | US20050043316 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same |
| 02/24/2005 | US20050043314 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 02/24/2005 | US20050043312 Nutraceuticals including folate, vitamin E, and acetyl-L-carnitine, and pharmaceuticals including 3-deaza-adenosine, N-acetyl-L-cysteine, and S-adenosylmethionine; Alzheimer's disease; amyotrophic lateral sclerosis (ALS) |
| 02/24/2005 | US20050043311 6(5-chloro-2-pyridyl-)-5-[4-methyl-1-piperazinyl]carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine for tranquilizers or hypnotics |
| 02/24/2005 | US20050043307 Novel heterocycle as agonist or antagonist for nervous systems which can contain double or triple bonds with nitrogen, oxygen or sulfur with carbon or azo groups and or salts and as modulators or receptors with carriers |
| 02/24/2005 | US20050043305 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 02/24/2005 | US20050043304 Lower alkyl molecular weight amine as enzyme inhibitors for use in the treatment of tryptase enzyme inhibitors inhibitorsfor respiratory system disorders, antiinflammatory agents, inflammatory bowel disease, hyperprolific skin disorders, vascular edema and rheumatoid arthritis |
| 02/24/2005 | US20050043303 prophylaxis of cardiovascular disorders comprising administering to mammals inhibitors of cyclic guanosine monophosphate metabolizing phosphodiesterases such as 2-{2-Ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-phenyl}-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one; antiarrythmic agents |
| 02/24/2005 | US20050043302 New indole derivatives as factor Xa inhibitors |
| 02/24/2005 | US20050043299 Inhibitors of dipeptidyl peptidase iv |
| 02/24/2005 | US20050043296 Compositions and methods for treating sexual dysfunction |
| 02/24/2005 | US20050043295 Pharmaceutically effective compounds |
| 02/24/2005 | US20050043293 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 02/24/2005 | US20050043289 cephalosporins; antimicrobial agent |
| 02/24/2005 | US20050043288 Composition and method for marking procaine penicillin |
| 02/24/2005 | US20050043287 Replacement for steroids and for stimulating an immune response; in a form which is palatable; acid pH less than 7.0; citric acid |
| 02/24/2005 | US20050043286 Use of an ascomycin for the treatment of blepharitis |
| 02/24/2005 | US20050043285 Formulation |
| 02/24/2005 | US20050043284 containing an anti-inflammatory and anti-allergic compound of the androstane series |
| 02/24/2005 | US20050043283 comprising a steroidal hormone (eg androgen) or anti-inflammatory agent (eg triamcinolone, hydrocortisone ); for cosmetics and dermatology |
| 02/24/2005 | US20050043282 for prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases |
| 02/24/2005 | US20050043281 administering for treatment of metabolic bone diseases, mobilizing calcium for osteoporosis, imbalances in the immune system |
| 02/24/2005 | US20050043280 reduced side effects |
| 02/24/2005 | US20050043274 Pharmaceutical compositions and methods for lowering blood pressure and pulse rate |
| 02/24/2005 | US20050043273 Compositions and methods for inhibiting slit protein and glypican interactions |
| 02/24/2005 | US20050043272 nanometer size; polysaccharide backbone linked with hydrophobic hydrocarbon group; small molecules are selected from antitumor agents, nucleic acids, peptides; renders a hydrophobic drug deliverable in a physiological fluid |
| 02/24/2005 | US20050043271 Heparin-containing ophthalmic agent |
| 02/24/2005 | US20050043270 administering hyaluronic acid or a pharmaceutically acceptable salt to a human or a non-human animal to treat Crohn disease or ulcerative colitis |
| 02/24/2005 | US20050043269 Pharmaceutically active uridine esters |
| 02/24/2005 | US20050043268 Inhibition of viruses |
| 02/24/2005 | US20050043263 First stretch is complementary to the nucleic acid coding for functional tumor suppressor for which the pathological cell is tumor suppressor-defective, second stretch is identical to the nucleic acid coding for the functional tumor suppressor for which pathological cell is tumor suppressor-defective |
| 02/24/2005 | US20050043253 polysporin or neosporin as wound healing agent for influenza virus administered topically to intranasal mucous membranes to provides a barrier that prevents the bacterial organism from systemic entry via the intranasal passage of the patient |
| 02/24/2005 | US20050043252 Pesticidal macrolides |
| 02/24/2005 | US20050043251 Method of treatment of otitis externa |
| 02/24/2005 | US20050043250 Cancer treatment including glycolytic inhibitors |
| 02/24/2005 | US20050043249 New pyrazole derivatives and diabetic medicine containing them |
| 02/24/2005 | US20050043247 Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative |
| 02/24/2005 | US20050043242 Using dietary restriction to lower serum insulin levels and function along with troglitazone in treatment and prevention of alzheimer's diseases |
| 02/24/2005 | US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer |
| 02/24/2005 | US20050043239 Administering phosphoinositide 3-kinase delta selective inhibitor effective to inhibit endogenous immune response stimulated by endogenous factor without inhibiting exogenous immune response stimulated by exogenous factor; treatment of Inflammatory responses, immune responses |
| 02/24/2005 | US20050043233 Comprising an antagonist of at least one receptor selected from VEGFR 1 to 3, PDGFR alpha and beta , FGFR1, 2 and 3, EGFR, HER2, IGF1R, HGFR or c-Kit, which is further an antagonist of a src tyrosine kinase family member, and a chemotherapeutic agent; co-treatment with radiation therapy |
| 02/24/2005 | US20050043231 Therapy for growth hormone induced insulin resistance in juveniles with growth disorders |